Receipt date: 04/23/2009 PTO/SB08a (05-07)
Approved for use through 08/09/2070, ORM 0651-0931
U.S. Patent and Trademark Office; U.S. DEPARTIMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10534922
Filing Date		2006-01-30
First Named Inventor	Philip	John Hogg
Art Unit	•	1614
Examiner Name	Chris	topher R. Stone
Attorney Docket Numb	oer	05-363

U.S.PATENTS Remove							
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	7074766	B1	2006-07-11	Hogg et al.		
	2	2409291		1946-10-15	Lott et al.		
	3	7186695	B2	2007-03-06	Hogg		
	4	5459263	A	1995-10-17	Floc'H et al.		
	5	2370092	A1	1945-02-20	Tillitson		
	6	2465308		1949-03-22	Herman et al.		
	7	2553515		1951-05-15	Herman et al.		
	8	2664432		1953-12-29	Friedheim		

				Filing	Date			2006-01-30				
INFORMATION DISCLOSURE			First Named Inventor Phili			nilip .	p John Hogg					
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art Unit			П	1614					
(NOT TOT :	subm	ission under 37 CFR	1.99)	Exam	iner Na	me Ch	nristo	opher R. Stone				
				Attorn	ey Doc	ket Number		05-363				
			1			1			r			
	9	5281588		1994-01	1-25	Maes et al.						
	10	2951766		1960-09	9-06	White						
W		14 - 44% 1110 D-4	-4 -14 - 41 -		-4'			I.I. In cast on		Add		
ır you wisi	n to ac	dd additional U.S. Pater								Remove		
			U.S.P	AIENI	APPLI	CATION PUB	SLIC	ATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pat of cited Docu		ee or Applicant ent	Relev	s,Columns,I ant Passag es Appear		
	1	20050101524	A1	2005-05	5-12	Hogg et al.						
	2	20070037996	A1	2006-05	5-22	Hogg et al.						
	3	20070037995	A1	2007-02	2-15	Hogg et al.						
If you wisl	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information	plea	ase click the Add	d butto	n. Add		
				FOREIG	3N PA1	TENT DOCUM	ИEN	ITS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	A	ame of Patente pplicant of cited ocument		where Rele	or Relevant	T5
	1											
If you wisl	h to ac	dd additional Foreign P	atent Do	cument	citation	information p	lea	se click the Add	buttor	Add		
			NON	I-PATE	NT LITE	RATURE DO	cu	MENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc),						T5

Application Number

10534922

Receipt date: 04/23/2009

Receipt date: 04/23/2009 Application Number 10534922 Filing Date 2006-01-30 INFORMATION DISCLOSURE First Named Inventor Philip John Hoga STATEMENT BY APPLICANT Art Unit 1614 (Not for submission under 37 CFR 1.99) Christopher R. Stone **Examiner Name** Attorney Docket Number 05-363

1		
2	HUMMEL et al., "Modification of Bovine Pancreatic Ribonuclease A with the Site-Specific Reagent 4-Arsono-2- nitrofluorobenzene. Spectrophotometric Titration of Arsononitrophenyl Ribonuclease A Derivatives", Biochemistry, 1981, Vol. 20, 4943-4952.	
3	HUMMEL et al., "Chemical modification of ribonuclease A with 4-arsono-2-nitrofluorobenzene", Int. J. Peptide Protein Res., 1984, Vol. 24, 1-13.	
4	DELNCMDEDIEU et al., "Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study", Chemico Biological Interactions, 1994, Vol. 90, 139-155.	
5	DCNCGHUE, N. et al., "Characterization of Redox-Active Proteins on Cell Surface", Methods in Enzymology, 2002, Vol. 348, 76-86.	
6	HNATOWICH, DJ et al., "Investigations of Avidin and Biotin for Imaging Applications", 1987, The Journal of Nuclear Medicine, Vol. 8, 1294-1302.	
7	GILL, B.S., "Chemotherapeutic Susceptibility of Trypanosoma to some Arsenicals and Suramin-Tryparsamid Complex", Acta Vet., 1971, 40(2), 209-14. (English Abstract only)	
8	YUKI, H. et al., "Synthesis of Purine and Pyrmidine Derivatives of Arsonic Acid", Chem. Pharm. Bull., 1967, 15(7), 1052-1055.	
9	DCNAHUE, N. et al., "[9] Identification of Redox-Active Proteins on Cell Surface, Methods of Enzymology, Vol. 352, 101-112.	
10	NAMGUNG et al., "Arsenite-Induced Apoptosis in Cortical Neurons is Mediated by c-Jun N-Terminal Protein Kinase 3 and p38 Mitogen-Activated Protein Kinase", The Journal of Neuroscience 2000, 20(7), 6442-6451.	
11	LOISEAU et al., "Contribution of Dithiol Ligands to In Vitro and In Vivo Trypanocidal Activities of Dithiaarsanes and ivestigation of Ligand Exchange in an Aqueous Solution", Antimicrobial Agents and Chemotherapy, 2000, 44(11) 2661-2661.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

05-363

Attorney Docket Number

	7 Montey Booket Humber 00 000	
12	GORMAN et al., "The Hype and the Hope", Time, 1998, 151(19), 40-44. Included HTML Copy referenced pages 1-9.	
13	GURA, T., "Systems for Identifying New Drugs are Often Faulty", Science, 1997, 278(7), 1041-1042.	
14	DERMER, GB, "Another Anniversary for the War on Cancer", Bio/Technology, March 12, 1994, Vol. 12, p. 320.	
15	MCKIE, R., "Cancer Research Set Back a Decade", The Observer, June 10, 2001, 1-4.	
16	Definition of Cancer. Internet document < > 1 page, accessed 9/16/05, last reviewed 9/18/2004.">> 1 page, accessed 9/16/05, last reviewed 9/18/2004.	
17	Chemical Abstracts Registry No. 1112-90-3. p-amino phenyl arsenoxide.	
18	Chemical Abstracts Registry No. 637-03-6. Arsenosobenzene.	
19	RUDINGER, J., "Characteristics of the amino acids as components of a peptide hormone sequence", In: Peptide Hormones, JA Parsons, Ed., 1976, 1-7.	
20	VOET et al., "Chapter 9. Hemoglobin: Protein Function in Microcosm, Section 9-3. Abnormal Hemoglobins", Biochemistry, 2nd Editon, 1995, 235-241.	
21	SMILEK et al., "A Single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis", Proc. Natl. Acad. Sci., 1991, Vol. 88, 9633-9637.	
22	BANKS et al., "Biomolecules Bearing the S- or SeAsMe2 Function: Amino Acid and Steroid Derivatives", Journal of Medicinal Chemistry, 1979, 22(5), 572-575.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

leceipt date: 04/23/2009	Application Number		10534922
	Filing Date		2006-01-30
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Philip	John Hogg
Not for submission under 37 CFR 1.99)	Art Unit		1614
	Examiner Name	Christ	topher R. Stone
	Attorney Docket Number	er	05-363

If you wish to add additional non-patent literature document citation information please click the Add button Add					
	EXAM	INER SIGNATURE			
Examiner Signature	/Craig Ricci/	Date Considered	09/09/2009		

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.